15 results about "HRT - Hormone replacement therapy" patented technology

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

The invention discloses a comprehensive climacteric woman health management system, and belongs to the technical field of health management. A comprehensive climacteric woman health management system comprises an information acquisition module, a health prediction module, a health guidance module and an information storage module. The problems that in the prior art, only the current health state of the climacteric woman can be evaluated, and hidden health problems and trends are difficult to find are solved, the information of the climacteric woman is stored by establishing the distributed storage area, the safety of long-term storage of the information of the climacteric woman is guaranteed, the resource utilization rate is optimized, and the user experience is improved. Potential risks of osteoporosis, hypertension, coronary heart disease and other diseases can be recognized, timely intervention is performed to delay or avoid disease development, the overall health level is improved, early psychological intervention is facilitated, common mood troubles in climacteric are relieved, the estrogen decline degree can be determined, a hormone replacement therapy scheme can be made in an assisted mode, and the development period of the disease is shortened. And the living quality of climacteric women is improved.

The invention pertains to pharmaceutical formulations, particularly sustained-release nanoparticle injections of nomegestrol acetate. These formulations are designed as lyophilized powder, enhancing the solubility, bioavailability, and therapeutic efficacy of nomegestrol acetate for medical applications. These pharmaceutical formulations are intended for diseases responsive to nomegestrol treatment, such as hormone replacement therapy. The lyophilized powder formulation is easily reconstituted and administered, improving overall patient experience and treatment outcomes

The present invention relates to therapeutic and non-therapeutic use of combinations of bacterial strains. In particular the use is for preventing or alleviating symptoms of menopause or climacteric symptom in a female mammal. Also disclosed herein are specific combinations of bacterial strains and their use in, as well as methods for reducing the need for estrogen replacement therapy, or for use in combination with estrogen replacement therapy, or other menopausal hormone replacement therapies.

The invention relates to the technical field of biology, in particular to application of a composition in preparation of drugs for preventing inflammatory aging and related diseases thereof. The composition provided by the invention is used for preventing atopic dermatitis (AD) recurrence, senile dermatitis and other BCAA metabolic disorder related skin diseases by selectively enhancing BCAT1 mediated branched chain amino acid (BCAA) degradation and reversing skin inflammatory aging. Clinical data show that after the composition provided by the invention is used for treatment, the recurrence rate of AD is reduced to 16.3% from 35.7%. The invention provides a non-hormone replacement therapy, which makes up the defects of the existing medicines, and the composition can be combined with the existing therapy during treatment, has high safety and no serious adverse reaction, and is suitable for long-term maintenance treatment.

A method of providing a culture of oogonia stem cells comprising oogonia stem cells is provided. The method may further include culturing the oogonia stem cells with granulosa and theca cells to differentiate the oogonia stem cells into oocytes. In some embodiments, the culturing comprises including the oogonia stem cells in an in vitro follicle construct or a microcapsule comprising said granulosa and theca cells. Further described herein is a method of forming a bioengineered follicle construct capable of releasing a mature oocyte. An in vitro fertilization method using the mature oocyte is also provided.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

1. A drug delivery device for use in treating one or more menopausal symptoms in a subject, comprising intravaginal insertion of an indwelling drug delivery device into the subject, wherein the drug delivery device comprises an estrogen and a progestin, and further provides a baseline-adjusted steady-state plasma estrogen concentration in the subject of about 15 pg / mL to about 50 pg / mL.

A drug delivery device for treating one or more symptoms of menopausal in a subject comprising intravaginal insertion of an implantable drug delivery device into the subject wherein the implantable drug delivery device comprises an estrogen and a progesterone, and further wherein the implantable drug delivery device provides a baseline adjusted homeostatic plasma estrogen concentration of from about 15 pg / mL to about 50 pg / mL in the subject.

Featured are compositions, methods, and apparatuses for biosynthetic organs, or organoids, that replicate tissues of the human female reproductive system (e.g., ovarian or uterine tissues). In particular, the disclosure features methods of culturing or 2024 / 054644 producing organoids or uteroids from pluripotent stem or progenitor cells and using the resulting organoids or uteroids to screen for safe and effective pharmaceutical interventions for diseases of interest. Such methods and compositions are particularly useful for the treatment of patients undergoing hormone replacement therapy (HRT) and / or assisted reproduction technology (ART) procedures, such as in vitro fertilization and in vitro oocyte maturation.WO

Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight / volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone.

A method for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17α-estradiol (E2a), 17β-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17α-dihydroequilin (EQa), 17β-dihydroequilin (EQb), Equilenin (EN), 17α-dihydroequilenin (ENa), 17β-dihydroequilenin (ENb), and Δ8,9-dehydroestrone (dE1)) in a sample by mass spectrometry includes ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

A method of providing a culture of oogonia stem cells comprising oogonia stem cells is provided. The method may further include culturing the oogonia stem cells with granulosa and theca cells to differentiate the oogonia stem cells into oocytes. In some embodiments, the culturing comprises including the oogonia stem cells in an in vitro follicle construct or a microcapsule comprising said granulosa and theca cells. Further described herein is a method of forming a bioengineered follicle construct capable of releasing a mature oocyte. An in vitro fertilization method using the mature oocyte is also provided.

A green light osteoporosis treatment device is provided. The device comprises a light irradiation chamber (1) (dimensions: 105 cm x 80 cm), multiple green LED light sources (with an emission wavelength of 520-525 nm) arranged within the chamber, and a light source control module (characterized by the module being able to adjust the illuminance of the LED light source to 400 lx). The green light with a wavelength of 520-525 nm and an illuminance of 400 lx is scientifically compatible with the GnIH hormone control mechanism, effectively suppressing osteoclast activity and preventing bone loss from the upstream stage. Compared to conventional drug therapy or electromagnetic therapy, this therapy has no chemical side effects and avoids the potential risks associated with hormone replacement therapy (HRT).